search
Back to results

Debio 0123 in Combination With Carboplatin and Etoposide in Adult Participants With Small Cell Lung Cancer That Recurred or Progressed After Previous Standard Platinum-Based Therapy

Primary Purpose

Small Cell Lung Cancer Recurrent

Status
Recruiting
Phase
Phase 1
Locations
International
Study Type
Interventional
Intervention
Debio 0123
Etoposide
Carboplatin
Sponsored by
Debiopharm International SA
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Small Cell Lung Cancer Recurrent focused on measuring Small cell lung cancer (SCLC), Recurrent, Debio 0123, Carboplatin, Etoposide, WEE1 inhibitor, WEE-1 inhibitor, Platinum-based therapy, Platinum-based chemotherapy

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Histologically or cytologically confirmed SCLC Tumor that is not bleeding Prior platinum-based chemotherapy (carboplatin and/or cisplatin) Part 1 (dose escalation): Recurrence or progression after a minimum of 45 days since the last dose of prior standard platinum-based therapy Part 2 (expansion): Recurrence or progression after a minimum of 90 days since the last dose of prior standard platinum-based therapy Measurable disease per RECIST 1.1 Willingness and ability to undergo tumor biopsy unless an archived tumor sample is available ECOG performance status of 0-1 Life expectancy of at least 3 months in the best judgment of the Investigator Adequate bone marrow, hepatic and renal function, adequate coagulation status Willingness and ability to comply with scheduled visits, study treatment plans, laboratory tests, and other study procedures. Exclusion Criteria: Use of an investigational agent or medical device within 28 days prior to first dose of study treatment. History of other malignancies requiring active treatment in the last 2 years prior to first dose of study treatment, except for superficial bladder cancers, ductal carcinoma in situ or other carcinomas in situ, and non-melanoma skin cancers (basal cell/squamous cell skin cancer) that have been treated with curative intent. History of myocardial infarction or stroke in the last 6 months prior to first dose of study treatment, congestive heart failure greater than New York Heart Association (NYHA) class II, unstable angina pectoris, unexplained recurrent syncope, cardiac arrhythmia requiring treatment, known family history of sudden death from cardiac-related causes before the age of 50, or any cardiotoxicity experienced after previous chemotherapy. Left ventricular ejection fraction (LVEF) below 55%. QTcF >450 ms, history of congenital long QT syndrome, or clinically significant conduction abnormality, or any conduction abnormality that may increase the risk of TdP. Clinically significant gastrointestinal abnormality that could affect the absorption of orally administered drugs Major surgery ≤4 weeks prior to first dose of study treatment or incomplete recovery from the surgical procedure at the time of the first dose of study treatment. Radiographic findings showing tumor involvement with large blood vessels or poor demarcation from them with increased risk for bleeding. Radiographic findings of Interstitial lung disease (ILD) that are considered clinically significant. Uncontrolled pleural effusion, pericardial effusion, or ascites requiring repeated drainage. Any infection requiring the systemic use of an antibiotic or antiviral agent. Known Hepatitis C virus (HCV), Hepatitis B virus (HBV), or Human Immunodeficiency Virus (HIV) infection. Participants with past infections that have been cured may be enrolled. Immunization with live or live-attenuated vaccine within 28 days prior to first dose of study treatment. Inability or unwillingness to swallow oral medications. Chemotherapy, monoclonal antibodies/biologics, or radiotherapy with curative intent within 28 days prior to first dose of study treatment. Palliative radiation is allowed up to 1 week prior to study treatment start. Unresolved AEs or toxicities due to previous treatments >Grade 1. Note: Participants with ≤Grade 2 alopecia or endocrinopathies controlled by replacement therapy are exceptions and may qualify for the study. Hypersensitivity to Debio 0123, etoposide or carboplatin, or any of the excipients found in the formulations for Debio 0123, etoposide, or carboplatin. If a prior hypersensitivity to carboplatin has been observed but a successful desensitization was performed for the participant, he or she may be eligible for the study. Prior exposure to any WEE1 inhibitor Note: Other inclusion/exclusion criteria mentioned in the protocol may apply.

Sites / Locations

  • Henry Ford Health System
  • Hospital Universitario Vall d'HebronRecruiting
  • Clinica Universidad de NavarraRecruiting
  • Hospital Universitario 12 de OctubreRecruiting
  • Hospital Universitario HM Sanchinarro. START Madrid - Centro Integral Oncológico Clara Campal (CIOCC)Recruiting
  • Clinica Universidad de NavarraRecruiting
  • Hospital Clinico Universitario de ValenciaRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Experimental

Arm Label

Part 1: Dose Escalation: Debio 0123 + Etoposide + Carboplatin

Part 2: Dose Expansion: Debio 0123 + Etoposide + Carboplatin

Arm Description

Participants will receive Debio 0123 escalating doses, orally along with etoposide IV infusion and carboplatin IV infusion in 21-day cycles until disease progression or death or end of study.

Participants will receive Debio 0123 RP2D determined in Part 1 of the study, orally along with etoposide IV infusion and carboplatin IV infusion in 21-day cycles until disease progression or death or end of study.

Outcomes

Primary Outcome Measures

Part 1: Number of Participants Experiencing Dose-limiting Toxicities (DLTs)
Parts 1 and 2: Number of Participants With at Least One Treatment Emergent Adverse Event (TEAE)
Parts 1 and 2: Number of Participants With Clinically Significant Abnormalities in Laboratory, Vital Signs, Electrocardiogram (ECG), and Echocardiogram Parameters
Parts 1 and 2: Change From Baseline in Eastern Cooperative Oncology Group Performance Status (ECOG PS)

Secondary Outcome Measures

Parts 1 and 2: Trough Concentration (Ctrough) of Debio 0123 and its Metabolite
Parts 1 and 2: Maximum Plasma Concentration (Cmax) of Debio 0123 and its Metabolite
Parts 1 and 2: Area Under the Concentration Curve Over 24 hours (AUC24h) of Debio 0123 and its Metabolite
Part 1: Time to Maximum Plasma Concentration (tmax) of Debio 0123 and its Metabolite
Part 1: Area Under the Concentration Curve up to the Last Measurable Concentration (AUClast) of Debio 0123 and its Metabolite
Part 1: Area Under the Concentration Curve up to Infinity (AUCinf) of Debio 0123 and its Metabolite
Part 1: Apparent Terminal Half-life (t1/2) of Debio 0123 and its Metabolite
Part 1: Apparent Clearance (CL/F) of Debio 0123
Part 1: Apparent Volume of Distribution (Vd/F) of Debio 0123
Part 1: Maximum Plasma Concentration (Cmax) of Etoposide
Part 1: Area Under the Concentration Curve Over 24 hours (AUC24h) of Etoposide
Part 1: Trough Concentration (Ctrough) of Etoposide
Part 1: Maximum Plasma Concentration (Cmax) of Carboplatin
Parts 1 and 2: Percentage of Participants With Best Overall Response (BOR) Assessed as per Response Evaluation Criteria in Solid Tumours (RECIST) 1.1 Criteria
Parts 1 and 2: Percentage of Participants With Objective Response (OR) Assessed as per RECIST 1.1 Criteria
Parts 1 and 2: Percentage of Participants With Disease Control (DC) Assessed as per RECIST 1.1 Criteria
Parts 1 and 2: Duration of Response (DOR) Assessed as per RECIST 1.1 Criteria
Parts 1 and 2: Progression Free Survival (PFS) Assessed as per RECIST 1.1 Criteria
Part 2: Overall Survival

Full Information

First Posted
March 9, 2023
Last Updated
September 27, 2023
Sponsor
Debiopharm International SA
search

1. Study Identification

Unique Protocol Identification Number
NCT05815160
Brief Title
Debio 0123 in Combination With Carboplatin and Etoposide in Adult Participants With Small Cell Lung Cancer That Recurred or Progressed After Previous Standard Platinum-Based Therapy
Official Title
A Phase 1 Dose-Escalation and Expansion Study to Assess Safety and Preliminary Antitumor Activity of Debio 0123 in Combination With Carboplatin and Etoposide in Adult Participants With Small Cell Lung Cancer That Recurred or Progressed After Previous Standard Platinum-Based Therapy
Study Type
Interventional

2. Study Status

Record Verification Date
September 2023
Overall Recruitment Status
Recruiting
Study Start Date
May 2, 2023 (Actual)
Primary Completion Date
January 2026 (Anticipated)
Study Completion Date
April 2026 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Debiopharm International SA

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
The primary purpose of part 1 (dose escalation) of this study is to identify the recommended phase 2 dose (RP2D) and to characterize the safety and tolerability of Debio 0123 in combination with carboplatin and etoposide. The primary purpose of part 2 (dose expansion) of this study is to characterize the safety and tolerability of Debio 0123 at the RP2D when administered in combination with carboplatin and etoposide.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Small Cell Lung Cancer Recurrent
Keywords
Small cell lung cancer (SCLC), Recurrent, Debio 0123, Carboplatin, Etoposide, WEE1 inhibitor, WEE-1 inhibitor, Platinum-based therapy, Platinum-based chemotherapy

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 1
Interventional Study Model
Sequential Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
54 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Part 1: Dose Escalation: Debio 0123 + Etoposide + Carboplatin
Arm Type
Experimental
Arm Description
Participants will receive Debio 0123 escalating doses, orally along with etoposide IV infusion and carboplatin IV infusion in 21-day cycles until disease progression or death or end of study.
Arm Title
Part 2: Dose Expansion: Debio 0123 + Etoposide + Carboplatin
Arm Type
Experimental
Arm Description
Participants will receive Debio 0123 RP2D determined in Part 1 of the study, orally along with etoposide IV infusion and carboplatin IV infusion in 21-day cycles until disease progression or death or end of study.
Intervention Type
Drug
Intervention Name(s)
Debio 0123
Intervention Description
Administered as capsules.
Intervention Type
Drug
Intervention Name(s)
Etoposide
Intervention Description
Administered as IV infusion.
Intervention Type
Drug
Intervention Name(s)
Carboplatin
Intervention Description
Administered as IV infusion.
Primary Outcome Measure Information:
Title
Part 1: Number of Participants Experiencing Dose-limiting Toxicities (DLTs)
Time Frame
Cycle 1 (Cycle=21 days)
Title
Parts 1 and 2: Number of Participants With at Least One Treatment Emergent Adverse Event (TEAE)
Time Frame
Approximately up to 44 months
Title
Parts 1 and 2: Number of Participants With Clinically Significant Abnormalities in Laboratory, Vital Signs, Electrocardiogram (ECG), and Echocardiogram Parameters
Time Frame
Approximately up to 44 months
Title
Parts 1 and 2: Change From Baseline in Eastern Cooperative Oncology Group Performance Status (ECOG PS)
Time Frame
Baseline up to approximately 44 months
Secondary Outcome Measure Information:
Title
Parts 1 and 2: Trough Concentration (Ctrough) of Debio 0123 and its Metabolite
Time Frame
For Part 1: Predose from Day 2 to Day 11 of Cycle 1; For Part 2: Predose from Day 3 to Day 10 of Cycle 1 and only Day 8 of subsequent cycles (Cycle=21 days)
Title
Parts 1 and 2: Maximum Plasma Concentration (Cmax) of Debio 0123 and its Metabolite
Time Frame
For Part 1: Multiple timepoints post dose from Day 1 to Day 11 of Cycle 1 (Cycle=21 days); For Part 2: Will be derived from the population Pharmacokinetic (PK) model using the sparse samples collected
Title
Parts 1 and 2: Area Under the Concentration Curve Over 24 hours (AUC24h) of Debio 0123 and its Metabolite
Time Frame
For Part 1: Multiple timepoints post dose from Day 1 to Day 11 of Cycle 1 (Cycle=21 days); For Part 2: Will be derived from the population PK model using the sparse samples collected
Title
Part 1: Time to Maximum Plasma Concentration (tmax) of Debio 0123 and its Metabolite
Time Frame
Multiple timepoints post dose from Day 1 to Day 11 of Cycle 1 (Cycle=21 days)
Title
Part 1: Area Under the Concentration Curve up to the Last Measurable Concentration (AUClast) of Debio 0123 and its Metabolite
Time Frame
Multiple timepoints post dose from Day 1 to Day 21 of Cycle 1 and Day 1 of Cycle 2 (Cycle=21 days)
Title
Part 1: Area Under the Concentration Curve up to Infinity (AUCinf) of Debio 0123 and its Metabolite
Time Frame
Multiple timepoints post dose from Day 1 to Day 21 of Cycle 1 and Day 1 of Cycle 2 (Cycle=21 days)
Title
Part 1: Apparent Terminal Half-life (t1/2) of Debio 0123 and its Metabolite
Time Frame
Multiple timepoints post dose from Day 1 to Day 21 of Cycle 1 and Day 1 of Cycle 2 (Cycle=21 days)
Title
Part 1: Apparent Clearance (CL/F) of Debio 0123
Time Frame
Multiple timepoints post dose from Day 1 to Day 21 of Cycle 1 and Day 1 of Cycle 2 (Cycle=21 days)
Title
Part 1: Apparent Volume of Distribution (Vd/F) of Debio 0123
Time Frame
Multiple timepoints post dose from Day 1 to Day 21 of Cycle 1 and Day 1 of Cycle 2 (Cycle=21 days)
Title
Part 1: Maximum Plasma Concentration (Cmax) of Etoposide
Time Frame
Multiple timepoints from administration to post dose from Day 1 to Day 3 of Cycle 1 (Cycle=21 days)]
Title
Part 1: Area Under the Concentration Curve Over 24 hours (AUC24h) of Etoposide
Time Frame
Multiple timepoints post dose from Day 1 to Day 5 of Cycle 1 (Cycle=21 days)
Title
Part 1: Trough Concentration (Ctrough) of Etoposide
Time Frame
Predose from Day 2 to Day 5 of Cycle 1 (Cycle=21 days)
Title
Part 1: Maximum Plasma Concentration (Cmax) of Carboplatin
Time Frame
Multiple timepoints from administration up to 6 hours post dose on Day 1 of Cycle 1 (Cycle=21 days)
Title
Parts 1 and 2: Percentage of Participants With Best Overall Response (BOR) Assessed as per Response Evaluation Criteria in Solid Tumours (RECIST) 1.1 Criteria
Time Frame
From the start of study treatment until disease progression or end of study (up to approximately 44 months)
Title
Parts 1 and 2: Percentage of Participants With Objective Response (OR) Assessed as per RECIST 1.1 Criteria
Time Frame
Up to end of study (approximately 44 months)
Title
Parts 1 and 2: Percentage of Participants With Disease Control (DC) Assessed as per RECIST 1.1 Criteria
Time Frame
From the start of study treatment until disease progression or end of study (up to approximately 44 months)
Title
Parts 1 and 2: Duration of Response (DOR) Assessed as per RECIST 1.1 Criteria
Time Frame
Up to disease progression or end of study (approximately 44 months)
Title
Parts 1 and 2: Progression Free Survival (PFS) Assessed as per RECIST 1.1 Criteria
Time Frame
From the start of study treatment until disease progression or death or end of study (up to approximately 44 months)
Title
Part 2: Overall Survival
Time Frame
From the start of study treatment until death from any cause or end of study (up to approximately 44 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Histologically or cytologically confirmed SCLC Tumor that is not bleeding Prior platinum-based chemotherapy (carboplatin and/or cisplatin) Part 1 (dose escalation): Recurrence or progression after a minimum of 45 days since the last dose of prior standard platinum-based therapy Part 2 (expansion): Recurrence or progression after a minimum of 90 days since the last dose of prior standard platinum-based therapy Measurable disease per RECIST 1.1 Willingness and ability to undergo tumor biopsy unless an archived tumor sample is available ECOG performance status of 0-1 Life expectancy of at least 3 months in the best judgment of the Investigator Adequate bone marrow, hepatic and renal function, adequate coagulation status Willingness and ability to comply with scheduled visits, study treatment plans, laboratory tests, and other study procedures. Exclusion Criteria: Use of an investigational agent or medical device within 28 days prior to first dose of study treatment. History of other malignancies requiring active treatment in the last 2 years prior to first dose of study treatment, except for superficial bladder cancers, ductal carcinoma in situ or other carcinomas in situ, and non-melanoma skin cancers (basal cell/squamous cell skin cancer) that have been treated with curative intent. History of myocardial infarction or stroke in the last 6 months prior to first dose of study treatment, congestive heart failure greater than New York Heart Association (NYHA) class II, unstable angina pectoris, unexplained recurrent syncope, cardiac arrhythmia requiring treatment, known family history of sudden death from cardiac-related causes before the age of 50, or any cardiotoxicity experienced after previous chemotherapy. Left ventricular ejection fraction (LVEF) below 55%. QTcF >450 ms, history of congenital long QT syndrome, or clinically significant conduction abnormality, or any conduction abnormality that may increase the risk of TdP. Clinically significant gastrointestinal abnormality that could affect the absorption of orally administered drugs Major surgery ≤4 weeks prior to first dose of study treatment or incomplete recovery from the surgical procedure at the time of the first dose of study treatment. Radiographic findings showing tumor involvement with large blood vessels or poor demarcation from them with increased risk for bleeding. Radiographic findings of Interstitial lung disease (ILD) that are considered clinically significant. Uncontrolled pleural effusion, pericardial effusion, or ascites requiring repeated drainage. Any infection requiring the systemic use of an antibiotic or antiviral agent. Known Hepatitis C virus (HCV), Hepatitis B virus (HBV), or Human Immunodeficiency Virus (HIV) infection. Participants with past infections that have been cured may be enrolled. Immunization with live or live-attenuated vaccine within 28 days prior to first dose of study treatment. Inability or unwillingness to swallow oral medications. Chemotherapy, monoclonal antibodies/biologics, or radiotherapy with curative intent within 28 days prior to first dose of study treatment. Palliative radiation is allowed up to 1 week prior to study treatment start. Unresolved AEs or toxicities due to previous treatments >Grade 1. Note: Participants with ≤Grade 2 alopecia or endocrinopathies controlled by replacement therapy are exceptions and may qualify for the study. Hypersensitivity to Debio 0123, etoposide or carboplatin, or any of the excipients found in the formulations for Debio 0123, etoposide, or carboplatin. If a prior hypersensitivity to carboplatin has been observed but a successful desensitization was performed for the participant, he or she may be eligible for the study. Prior exposure to any WEE1 inhibitor Note: Other inclusion/exclusion criteria mentioned in the protocol may apply.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Debiopharm International S.A
Phone
+41 21 321 01 11
Email
clinicaltrials@debiopharm.com
Facility Information:
Facility Name
Henry Ford Health System
City
Detroit
State/Province
Michigan
ZIP/Postal Code
48202
Country
United States
Individual Site Status
Not yet recruiting
Facility Name
Hospital Universitario Vall d'Hebron
City
Barcelona
ZIP/Postal Code
08035
Country
Spain
Individual Site Status
Recruiting
Facility Name
Clinica Universidad de Navarra
City
Madrid
ZIP/Postal Code
28027
Country
Spain
Individual Site Status
Recruiting
Facility Name
Hospital Universitario 12 de Octubre
City
Madrid
ZIP/Postal Code
28041
Country
Spain
Individual Site Status
Recruiting
Facility Name
Hospital Universitario HM Sanchinarro. START Madrid - Centro Integral Oncológico Clara Campal (CIOCC)
City
Madrid
ZIP/Postal Code
28050
Country
Spain
Individual Site Status
Recruiting
Facility Name
Clinica Universidad de Navarra
City
Pamplona
ZIP/Postal Code
31008
Country
Spain
Individual Site Status
Recruiting
Facility Name
Hospital Clinico Universitario de Valencia
City
Valencia
ZIP/Postal Code
46010
Country
Spain
Individual Site Status
Recruiting

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Debio 0123 in Combination With Carboplatin and Etoposide in Adult Participants With Small Cell Lung Cancer That Recurred or Progressed After Previous Standard Platinum-Based Therapy

We'll reach out to this number within 24 hrs